Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy.

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: N.F. received travel funds for research meetings from Novartis. M.H. received speaking fees and travel funds from Bayer HealthCare, Biogen, Merck Serono, Novartis and Teva. U.K.Z. received speaking fees, travel support and financial support for research activities from Alexion, Almirall, Bayer, Biogen, Bristol Myers Squibb, Janssen, Merck Serono, Novartis, Octapharma, Roche, Sanofi Genzyme, Teva and EU, BMBF, BMWi and DFG. M-C.H., S.E.L., P.M., J.L.D., B.S., J.B. and F.H. declare no competing interests."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."